Legal & General Group PLC Solid Biosciences Inc. Transaction History

Legal & General Group PLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 22, 2022	SELL	$0.43 - $1.24 $2,047 - $5,904	-4,762 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$3.49 - $5.51 $7,608 - $12,011	2,180 Added 84.43%	4,762 $17,000
Q1 2021 May 17, 2021	BUY	$5.37 - $10.72 $2,260 - $4,513	421 Added 19.48%	2,582 $14,000
Q3 2020 Nov 13, 2020	SELL	$2.02 - $3.08 $2,444 - $3,726	-1,210 Reduced 35.89%	2,161 $4,000
Q2 2020 Aug 14, 2020	BUY	$2.1 - $3.42 $1,360 - $2,216	648 Added 23.8%	3,371 $10,000
Q1 2020 May 14, 2020	SELL	$2.31 - $4.43 $2,483 - $4,762	-1,075 Reduced 28.3%	2,723 $7,000
Q4 2019 Feb 13, 2020	BUY	$2.82 - $12.9 $346 - $1,586	123 Added 3.35%	3,798 $17,000
Q3 2019 Nov 13, 2019	BUY	$4.33 - $11.64 $5,360 - $14,410	1,238 Added 50.8%	3,675 $38,000
Q1 2019 May 15, 2019	BUY	$7.19 - $32.37 $1,524 - $6,862	212 Added 9.53%	2,437 $23,000
Q4 2018 Feb 15, 2019	BUY	$21.32 - $46.34 $8,528 - $18,536	400 Added 21.92%	2,225 $60,000
Q3 2018 Nov 20, 2018	BUY	$36.35 - $51.7 $21,446 - $30,503	590 Added 47.77%	1,825 $86,000
Q2 2018 Aug 10, 2018	SELL	$7.33 - $43.15 $2,675 - $15,749	-365 Reduced 22.81%	1,235 $44,000
Q1 2018 May 17, 2018	BUY	$7.19 - $33.17 $11,504 - $53,072	1,600 New	1,600 $12,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $36.5M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.